Apoprotein E and Reverse Cholesterol Transport

Getz, Godfrey S.; Reardon, Catherine A.

doi:10.3390/ijms19113479

Cited by 76 publications

(52 citation statements)

References 50 publications

(53 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The function of apoE in macrophages that is thought to be most important for its anti-atherogenic role is its ability to enhance cholesterol efflux from the arterial macrophages, thereby reducing their lipid burden and the subsequent downstream production of macrophage products, such as pro-inflammatory cytokines and chemokines that promote atherogenesis (Table 1). We have recently reviewed the role of apoE in cellular cholesterol efflux and reverse cholesterol transport (Getz and Reardon, 2018). Most studies of cholesterol efflux in vitro and in vivo use mouse macrophage cell lines, such as J774A.1 or RAW264.7 cells.…”

Section: The Influence Of Apoe On Macrophages and Monocytesmentioning

confidence: 99%

Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis

Getz

Reardon

2019

Front. Pharmacol.

View full text Add to dashboard Cite

Macrophages are core cellular elements of both early and advanced atherosclerosis. They take up modified lipoproteins and become lipid-loaded foam cells and secrete factors that influence other cell types in the artery wall involved in atherogenesis. Apoproteins E, AI, and SAA are all found on HDL which can enter the artery wall. In addition, apoE is synthesized by macrophages. These three apoproteins can promote cholesterol efflux from lipid-loaded macrophages and have other functions that modulate macrophage biology. Mimetic peptides based on the sequence or structure of these apoproteins replicate some of these properties and are potential therapeutic agents for the treatment of atherosclerosis to reduce cardiovascular diseases.

show abstract

Section: The Influence Of Apoe On Macrophages and Monocytesmentioning

confidence: 99%

Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis

Getz

Reardon

2019

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The main mechanisms of action of apoA-I and apoE mimetics are theoretically different, since apoE mimetics mediate hepatic clearance of atherogenic apoB-containing lipoproteins from the circulation via interaction with lipoprotein receptors, whereas apoA-I mimetics mainly stimulate the reverse cholesterol transport pathway [ 11 ]. Additionally, apoE mimetics enhance cholesterol efflux from cholesterol-loaded macrophages [ 14 ]. However, both groups of mimetics have also shown anti-inflammatory and antioxidant properties, avoiding the oxidation of LDL by sequestering lipoperoxides [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

et al. 2020

View full text Add to dashboard Cite

Mimetic peptides are potential therapeutic agents for atherosclerosis. d-[113–122]apolipoprotein (apo) J (d-[113–122]apoJ) is a 10-residue peptide that is predicted to form a class G* amphipathic helix 6 from apoJ; it shows anti-inflammatory and anti-atherogenic properties. In the present study, we analyzed the effect of d-[113–122]apoJ in low-density lipoprotein receptor knockout mice(LDLR-KO) on the development of atherosclerosis and lipoprotein function. Fifteen-week-old female LDLR-KO mice fed an atherogenic Western-type diet were treated for eight weeks with d-[113–122]apoJ peptide, a scrambled peptide, or vehicle. Peptides were administered subcutaneously three days per week (200 µg in 100 µL of saline). After euthanasia, blood and hearts were collected and the aortic arch was analyzed for the presence of atherosclerotic lesions. Lipoproteins were isolated and their composition and functionality were studied. The extent of atherosclerotic lesions was 43% lower with d-[113–122]apoJ treatment than with the vehicle or scramble. The lipid profile was similar between groups, but the high-density lipoprotein (HDL) of d-[113–122]apoJ-treated mice had a higher antioxidant capacity and increased ability to promote cholesterol efflux than the control group. In addition, low-density lipoprotein (LDL) from d-[113–122]apoJ-treated mice was more resistant to induced aggregation and presented lower electronegativity than in mice treated with d-[113–122]apoJ. Our results demonstrate that the d-[113–122]apoJ peptide prevents the extent of atherosclerotic lesions, which could be partially explained by the improvement of lipoprotein functionality.

show abstract

“…ApoCs and apoEs are interchangeable between complexes during the conversion of VLDL to LDL. ApoEs may function as a lecithin-cholesterol acyltransferase (LCAT) activator and influence the activity of hepatic lipase and CETP [19,20].…”

Section: Apolipoproteins and Lipoprotein-associated Proteinsmentioning

confidence: 99%

Lipoproteomics: Methodologies and Analysis of Lipoprotein-Associated Proteins along with the Drug Intervention

Torres‐Romero¹,

Lara-Riegos²,

Parra³

et al. 2021

Drug Design - Novel Advances in the Omics Field and Applications

View full text Add to dashboard Cite

Lipoproteins are specialized particles involved in the transport and distribution of hydrophobic lipids, as cholesterol and triglycerides, throughout the body. The lipoproteins exhibit a basic spherical shape as complexes of lipids and proteins, and these latter are known as apolipoproteins. Initially, the proteins associated with lipoproteins were recognized as integral or peripheral proteins that only maintain the dynamics and metabolism of lipoproteins. However, there exist many studies on different lipoproteins evidencing that the quantity and type of apolipoproteins and lipoprotein-associated proteins are diverse and could be associated with different lipoprotein function outcomes. Here, we summarized recent processes in the determination of apolipoproteins and lipoprotein-associated proteins profiles through a proteomic approach, analyzing the major methods available and are used to achieve this. We also discuss the relevance of these lipoproteomic analyses on the human disease outcomes.

show abstract

Apoprotein E and Reverse Cholesterol Transport

Cited by 76 publications

References 50 publications

Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis

Apoproteins E, A-I, and SAA in Macrophage Pathobiology Related to Atherogenesis

Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice

Lipoproteomics: Methodologies and Analysis of Lipoprotein-Associated Proteins along with the Drug Intervention

Contact Info

Product

Resources

About